Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib with Palbociclib and Fulvestrant in Advanced Breast Cancer
NCT04483505Phase 1Completed
- Sponsor
- Fundación CRIS contra el Cáncer
- Start
- Nov 2020
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rogaratinib in breast cancer, sponsored by Fundación CRIS contra el Cáncer. Primary endpoints: Recommended Phase 2 Dose at 2 months and Incidence of Treatment-Emergent Adverse Event at 2 years. Started Nov 2020; status: completed.
02
Drugs
rogaratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04483505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483505.